ReviewJournal of translational medicine2026
Integrin-mediated mechanotransduction in the tumor microenvironment: macrophage-centered signaling mechanisms and immune remodeling.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTumor-associated macrophages (TAMs) play a critical role in the immunosuppressive tumor microenvironment (TME). Although the biochemical signaling pathways regulating TAMs have been extensively elucidated, how these cells persistently sense physical properties of the tumor stroma-such as matrix stiffness, tension, and compression-and translate them into sustained immunosuppressive programs remains to be systematically addressed. MAIN BODY: Unlike other infiltrating immune cell populations that primarily engage in transient adhesive interactions, TAMs utilize integrins for stable spatial anchoring and continuous mechanotransduction. In this review, we synthesize current evidence on the integrin-TAM mechanosensing axis. We first distinguish the persistent mechanobiological features of TAMs from those of structural stromal cells and other transiently infiltrating lymphocytes. Subsequently, we delineate how force-dependent signaling shapes TAM phenotypic plasticity, metabolic reprogramming, and spatial organization. Crucially, we define a self-amplifying biomechanical-immune feedback framework, demonstrating how mechanically remodeled TAMs actively exacerbate extracellular matrix stiffening to consolidate the immunosuppressive niche. Furthermore, we critically evaluate the translational relevance of this axis, analyzing the limitations of past single-target integrin inhibitors and highlighting the emerging potential of multidimensional combination therapeutic strategies.
conclusionsTargeting integrin-dependent mechanotransduction provides a rational, system-level strategy to dismantle mechanically reinforced immune barriers. Breaking this interlocking feedback framework offers new insights for remodeling the TME and enhancing the efficacy of current immunotherapies.
Indexed as
Identifiers
42421096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.